Upstream / Downstream

Explore pathways related to this product.

Our U.S. Offices Will Be Closing Early

Our U.S. offices will be closing early on November 24th at 6:00 PM EST.

To Purchase # 8915LC

8915LC 10 µg (With Carrier) $199.00
8915LF 10 µg (Carrier Free) $199.00
$ 0. 00

Questions?

Find answers on our FAQs page.

ANSWERS  

Visit PhosphoSitePlus®

PTM information and tools available.

LEARN MORE

Source / Purification

Recombinant human TGF-β1 (hTGF-β1) Ala279-Ser390 (Accession #P01137) was expressed in human 293 cells at Cell Signaling Technology.

Product Description

Purity:

>98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant hTGF-β1. Less than 1% migrates as monomer hTGF-β1 under non-reduced (-) conditions. All lots are greater than 98% pure.


Molecular Formula:

Recombinant hTGF-β1 contains no "tags" and the nonglycosylated protein has a calculated MW of 12,794. DTT-reduced protein migrates as a 13 kDa polypeptide and the non-reduced cystine-linked homodimer migrates as a 25 kDa protein. The expected amino-terminal ALDTN of recombinant hTGF-β1 was verified by amino acid sequencing.


Bioactivity:

The bioactivity of recombinant hTGF-β1 was determined by assessing inhibition of IL-4 induced HT-2 cell proliferation. The ED50 of each lot is between 0.04-0.20 ng/ml.


Endotoxin:

Less than 0.01 ng endotoxin/1 μg hTGF-β1.


Product Usage Information

Formulation:

With carrier: Lyophilized from a 0.22 μm filtered solution of 20 mM citrate, pH 3.0 containing 100 mM NaCl and 20 μg BSA per 1 μg hTGF-β1. Carrier free: Lyophilized from a 0.22 μm filtered solution of 20 mM citrate, pH 3.0 containing 100 mM NaCl.


Storage: Stable in lyophilized state at 4°C for 1 year after receipt. Sterile stock solutions reconstituted with carrier protein are stable at 4°C for 2 months and at -20°C for 6 months. Avoid repeated freeze-thaw cycles.Maintain sterility. Storage at -20°C should be in a manual defrost freezer.

TGF-β1 activities include proliferation, angiogenesis and promotion or inhibition of many immune events (1-3). TGF-β1 is produced by a number of cell types including regulatory T cells, fibroblasts, epithelial cells, and endothelial cells (3). TGF-β1 binds to TβRII homodimer, which then complexes with TβRI homodimer (1,4). The oligomeric receptor complex phosphorylates subsets of the SMAD proteins that then act to induce and repress a number of target genes (1,3,4). TGF-β1 binding can also activate the Erk2, p38, and JNK pathways via TAK1 (4). TGF-β1 appears to promote late stage progression and metastasis in some cancers (1,2).


1.  Siegel, P.M. and Massagué, J. (2003) Nat Rev Cancer 3, 807-21.

2.  Bierie, B. and Moses, H.L. (2006) Nat Rev Cancer 6, 506-20.

3.  Tian, M. and Schiemann, W.P. (2009) Future Oncol 5, 259-71.

4.  Moustakas, A. and Heldin, C.H. (2009) Development 136, 3699-714.


Entrez-Gene Id 7040
Swiss-Prot Acc. P01137


For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.